Picture this: your doctor mentions GLP-1 medications at your annual checkup, hands you a list of telehealth options, and suddenly you’re down a rabbit hole of subscription fees, compound pharmacy disclaimers, and wildly different monthly prices. That was me in January. The options are genuinely confusing, and the stakes feel high enough that I didn’t want to just pick whoever had the slickest ad on Instagram.
What follows is the shortlist I actually landed on after sorting through pricing, pharmacy transparency, clinical oversight, and which providers survived the early-2026 regulatory pressure relatively intact. I’m not a doctor. This isn’t medical advice. But if you’re a real adult trying to make a smart choice, here’s what I found.
1. HealthRX
Start here on price alone. Compounded semaglutide from $99 a month and compounded tirzepatide from $149 a month puts HealthRX at the bottom of the cost range for any telehealth option I looked at that still includes physician oversight. That’s not a promotional teaser rate requiring a six-month commitment. It’s the entry price.
The pharmacy question matters more than most comparison articles admit. A lot of telehealth companies ship from compounding pharmacies they never name. HealthRX dispenses through Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from compounding bench to your door. LegitScript has certified them (certification 50087439, which you can look up yourself). That’s a meaningful layer of accountability that vague “licensed pharmacy partner” language doesn’t give you.
The clinical model is straightforward: fill out an online health assessment, a board-certified U.S. physician reviews it within roughly 24 hours, and medication ships overnight at no extra charge to all 50 states. Free overnight delivery everywhere is not standard. Most providers either charge for it or simply don’t offer it to certain states.
On efficacy: HealthRX cites the published clinical trial data, not its own outcomes. The STEP 1 trial showed roughly 15% body weight reduction with semaglutide at 68 weeks; the SURMOUNT-1 trial showed around 21% with tirzepatide at 72 weeks. Those are trial results under controlled conditions, not guarantees for any individual.
Compounded medications are not FDA-approved. Worth saying plainly.
2. Mochi Health
Mochi is one of the few telehealth GLP-1 providers staffed specifically by board-certified obesity medicine physicians rather than general practitioners. That distinction changes the quality of the conversation you have at intake. Monthly costs start at about $99 for compounded semaglutide and roughly $199 for compounded tirzepatide. The monitoring is more involved than some bare-bones platforms, which appeals to people who want clinical engagement beyond just the prescription.
3. FormBlends
FormBlends earns a spot on this list for a specific reason: published purity testing. Most telehealth GLP-1 providers tell you their pharmacy is reputable. FormBlends publishes actual HPLC purity figures, mass spec identity results, and endotoxin sterility data for their products. If you want to see the numbers rather than take someone’s word for it, that’s a real differentiator.
The platform operates under physician oversight and dispenses through an FDA-registered 503A compounding pharmacy. It ships to 47 states, which is slightly narrower than HealthRX’s full 50-state reach. Pricing is higher: semaglutide around $299 per vial and tirzepatide around $349. For someone focused purely on monthly cost, HealthRX wins. But FormBlends is the better call if you want documented purity data or if you’re also interested in recovery, longevity, or cognitive peptides, because FormBlends carries a broader peptide catalog under the same clinician model. Almost no GLP-1-only telehealth brand offers that combination.
4. Ro Body
Ro’s membership model starts at roughly $39 for the first month, then sits around $74 to $149 per month, with medications billed separately. The meaningful advantage here is their prior-authorization team, which actively works with insurance companies to get branded GLP-1 medications covered. If you have insurance that might cover Wegovy or Zepbound and you’re willing to do the paperwork process, Ro’s infrastructure for that is genuinely useful. Cash-pay patients on a tight budget will probably find better total cost elsewhere.
5. Hims & Hers
Hims & Hers exited the compounded GLP-1 market following the Novo Nordisk settlement in March 2026 and now focuses on branded medications. Injectable Wegovy runs around $299 a month through their platform, oral semaglutide around $249, and Zepbound around $399. With insurance and a manufacturer savings card, some patients get down to $0 to $25 a month. The brand-name-only direction makes this a strong option for people with good insurance or access to those savings programs, less compelling for cash-pay patients.
6. PlushCare
PlushCare is worth mentioning for people who want same-day appointments. Membership runs about $19.99 a month, branded medications are prescribed and billed separately, and they accept insurance. It’s a general-purpose telehealth platform rather than a GLP-1-focused one, so the obesity medicine depth isn’t there, but the speed and insurance compatibility are real advantages for the right patient profile.
A Practical Note Before You Start
The early months of 2026 brought FDA warning letters to more than 30 compounding telehealth companies. The regulatory situation around compounded GLP-1 medications is genuinely shifting. Before you sign up for anything, confirm that the pharmacy your provider uses is currently operating in compliance, ask who the dispensing pharmacy is by name, and talk to your own physician about whether a compounded or branded medication is the right fit for your specific health history. Nothing on this page replaces that conversation.
Common Questions
Is compounded semaglutide from a telehealth clinic the same drug as Wegovy?
Compounded semaglutide contains the same active molecule, but it is not FDA-approved and is not manufactured by Novo Nordisk. Quality depends entirely on the compounding pharmacy’s standards. Providers like FormBlends publish HPLC and mass spec data; others offer only general assurances. Ask for documentation before committing.
Why does HealthRX cost $99 a month when FormBlends charges $299 per vial for the same compound?
Price differences reflect pharmacy sourcing, testing depth, overhead, and margin decisions. HealthRX’s lower price includes physician review and overnight shipping. FormBlends charges more partly because it publishes independent purity data, which costs money to produce. Neither price alone tells you which product is safer or more effective.
If Hims & Hers stopped selling compounded semaglutide, what happens to patients already on their program?
Following the March 2026 Novo Nordisk settlement, Hims & Hers shifted to branded medications. Patients previously on compounded versions would need to transition to branded Wegovy or Zepbound through the platform, or move to a provider still dispensing compounded product, assuming they remain eligible under their state’s prescribing rules.
Does Mochi Health’s obesity medicine specialist model actually change outcomes, or is it just a credential?
Board-certified obesity medicine physicians are specifically trained in metabolic disease, not just weight management in passing. That training affects how they handle dose escalation, side effect management, and comorbidities like type 2 diabetes. Whether it improves your personal outcome depends on how much you engage with the clinical team, but the depth of expertise available is genuinely different from a general-practice telehealth model.
Can Ro Body actually get insurance to cover Wegovy or Zepbound, or is that mostly theoretical?
Ro has a dedicated prior-authorization team that submits the paperwork and follows up with insurers. Coverage is real for some patients, particularly those with a documented BMI over 30 or obesity-related conditions, but it depends entirely on your specific plan. It is not guaranteed, and many commercial plans still exclude GLP-1 medications for weight loss even in 2026.
Sources
- FDA, Warning Letters to Compounding Facilities (2026), publicly listed at FDA.gov
- Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide STEP 1 outcomes)
- Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide SURMOUNT-1 outcomes)
- LegitScript pharmacy certification database (public search tool)
- Novo Nordisk settlement press coverage, Reuters and STAT News, March 2026
- Lilly Direct orforglipron pricing, LillyDirect.com announcement, April 2026
